Literature DB >> 10841214

Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons.

K Mishima1, M Okawa, S Hozumi, Y Hishikawa.   

Abstract

Increased daytime napping, early morning awakening, frequent nocturnal sleep interruptions, and lowered amplitude and phase advance of the circadian sleep-wake rhythm are characteristic features of sleep-waking and chronobiological changes associated with aging. Especially in elderly patients with dementia, severely fragmented sleep-waking patterns are observed frequently and are associated with disorganized circadian rhythm of various physiological functions. Functional and/or organic deterioration of the suprachiasmatic nucleus (SCN), decreased exposure to time cues such as insufficient social interaction and reduced environmental light, lowered sensitivity of sensory organs to time cues, and reduced ability of peripheral effector organs to express circadian rhythms may cause these chronobiological changes. In many cases of dementia, the usual treatments for insomnia do not work well, and the development of an effective therapy is an important concern for health care practitioner and researchers. Recent therapeutical trials of supplementary administration of artificial bright light and the pineal hormone melatonin, a potent synchronizer for mammalian circadian rhythm, have indicated that these treatments are useful tools for demented elderly insomniacs. Both bright light and melatonin simultaneously ameliorate disorganized thermoregulatory and neuroendocrine systems associated with disrupted sleep-waking times, suggesting a new, potent therapeutic means for insomnia in the demented elderly. Future studies should address the most effective therapeutic design and the most suitable types of symptoms for treatment and investigate the use of these tools in preventive applications in persons in early stages of dementia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841214     DOI: 10.1081/cbi-100101055

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  24 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 3.  Pharmacotherapies for sleep disturbances in dementia.

Authors:  Jenny McCleery; Daniel A Cohen; Ann L Sharpley
Journal:  Cochrane Database Syst Rev       Date:  2016-11-16

Review 4.  Sleep Disturbance, Cognitive Decline, and Dementia: A Review.

Authors:  Alexandra M V Wennberg; Mark N Wu; Paul B Rosenberg; Adam P Spira
Journal:  Semin Neurol       Date:  2017-08-24       Impact factor: 3.420

Review 5.  The circadian clock and pathology of the ageing brain.

Authors:  Anna A Kondratova; Roman V Kondratov
Journal:  Nat Rev Neurosci       Date:  2012-03-07       Impact factor: 34.870

Review 6.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

7.  Improved cognitive morning performance in healthy older adults following blue-enriched light exposure on the previous evening.

Authors:  Karine Scheuermaier; Mirjam Münch; Joseph M Ronda; Jeanne F Duffy
Journal:  Behav Brain Res       Date:  2018-04-21       Impact factor: 3.332

8.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

9.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 10.  Sleep in older adults: normative changes, sleep disorders, and treatment options.

Authors:  Nalaka S Gooneratne; Michael V Vitiello
Journal:  Clin Geriatr Med       Date:  2014-06-12       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.